Precision Diabetes Is Slowly Becoming a Reality
Open Access
- 27 January 2019
- journal article
- review article
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 28 (1) , 1-9
Abstract
The concept of precision medicine is becoming increasingly popular. The use of big data, genomics and other “omics” like metabolomics, proteomics and transcriptomics could make the dream of personalised medicine become a reality in the near future. As far as polygenic forms of diabetes like type 2 and type 1 diabetes are concerned, interesting leads are emerging, but precision diabetes is still in its infancy. However, with regard to monogenic forms of diabetes like maturity-onset diabetes of the young and neonatal diabetes mellitus, rapid strides have been made and precision diabetes has already become part of the clinical tools used at advanced diabetes centres. In patients with some monogenic form of diabetes, if the appropriate gene defects are identified, insulin injections can be stopped and be replaced by oral sulphonylurea drugs. In the coming years, rapid advances can be expected in the field of precision diabetes, thereby making the control of diabetes more effective and hopefully leading to prevention of its complications and improvement of the quality of life of people afflicted with diabetes.Keywords
This publication has 75 references indexed in Scilit:
- Preparing for Precision MedicineNew England Journal of Medicine, 2012
- Pharmacogenetics in type 2 diabetes: potential implications for clinical practiceGenome Medicine, 2011
- Common variants near ATM are associated with glycemic response to metformin in type 2 diabetesNature Genetics, 2010
- Expression of Organic Cation Transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) Is Affected by Genetic Factors and Cholestasis in Human Liver†Hepatology, 2009
- A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemiaProceedings of the National Academy of Sciences, 2009
- Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS StudyDiabetes, 2009
- Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and KoreaDiabetes Research and Clinical Practice, 2009
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJournal of Clinical Investigation, 2007
- Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 MutationsNew England Journal of Medicine, 2006
- Dr. Karl Landsteiner—Nobel Prize Laureate in Medicine, 1930Science, 1931